5th and 6th Sero Survey of Delhi: Vaccine Activated Antibodies Enhancement
##plugins.themes.bootstrap3.article.main##
The results of all six serosurveys of Delhi (India) have been analysed. The first serosurvey held in June-July 2020 found seroprevalence in 22.9% population. The second, third, and fourth survey conducted in August, September, and October registered 29.1%, 25.1%, and 25.5% seropositivity, respectively. The seroprevalence was increased to a larger extent of 56.1% in the fifth (January 2021) survey due to the accumulation of antibodies among the residents in three pandemic waves that hit the city in June, September, and November 2020. The last and the fourth bigger wave that hit the city in April 2021 caused almost all (97%) citizens to develop antibodies against the natural COVID-19 infection. The seroprevalence in women was marginally higher (90%) than in men (88%). The seroprevalence was highest (92%) among the individuals above 50 years of age followed by 18-49 years of age (90%) and 82% in below 18 years of age. The residents who were vaccinated with Covishield produced slightly higher antibodies (95%) than Covaxin (93%). In Delhi,one dose or two doses vaccination could increase seroprevalence to 95% that was the maximum which vaccination could generate. The unvaccinated population had seroprevalence of 85%. A maximum enhancement of 13% seroprevalence was recorded upon vaccination with one or two doses.
Downloads
References
-
Covid-19 global death toll tops 5 million in under 2 years. [Internet] [cited November 1, 2021] The Times of India.
Google Scholar
1
-
Shervani Z, Bhardwaj D, Nikhat R, Ibbrahim A, Khan I, Qazi UY, et al. 4th National Sero Survey of India: Vaccine Generated Antibodies Enhancement, European Journal of Health and Medical Sciences. 2021 (in press).
Google Scholar
2
-
WHO raises alarm over fresh Covid surge in Europe: All you need to know. [Internet] [cited November 6, 2021] Hindustan Times.
Google Scholar
3
-
Global Covid-19 tally crosses 250 million: Report. [Internet] [cited November 9, 2021] Hindustan Times.
Google Scholar
4
-
Russia sees record daily Covid-19 cases despite paid holiday. [Internet] [cited November 6, 2021] Hindustan Times.
Google Scholar
5
-
New Zealand's daily coronavirus cases cross 200 for first time in pandemic. [Internet] [cited November 6, 2021] Reuters.
Google Scholar
6
-
At 10,929, India sees less than 11,000 fresh Covid-19 cases for 2nd time this week. [Internet] [cited November 6, 2021] Hindustan Times.
Google Scholar
7
-
Coronavirus (COVID-19)-Google News-India.
Google Scholar
8
-
India’s COVID-19 cases hit 9-month low. [Internet] [cited November 6, 2021] The Hindu.
Google Scholar
9
-
Covid-19:78% people received first dose of vaccine, 35% fully jabbed, says Mandaviya. [Internet] [cited November 1, 2021] Hindustan Times.
Google Scholar
10
-
Japan reports no COVID-related deaths for the first time in 15 months. [Internet] [cited November 7, 2021] The Japan Times.
Google Scholar
11
-
Britain approves Merck’s COVID-19 pill in world first. [Internet] [cited November 5, 2021] Reuters.
Google Scholar
12
-
Pfizer develops COVID-19 pill that cuts hospitalizations and deaths by 89%. [Internet] [cited November 5, 2021] The Japan Times.
Google Scholar
13
-
COVID-19 drugs will change the way we live with the virus. [Internet] [cited November 7, 2021] The Japan Times.
Google Scholar
14
-
Pfizer to seek OK for use of COVID-19 shot in children in Japan age 5 to 11. [Internet] [cited October 28, 2021] The Japan Times.
Google Scholar
15
-
Zydus jab cleared for kids to cost govt ₹265. [Internet] [cited November 9, 2021] Hindustan Times.
Google Scholar
16
-
UK allows early booking of booster shots to ramp up vaccine rollout. [Internet] [cited November 6, 2021] Hindustan Times.
Google Scholar
17
-
Belgium plans COVID-19 booster shot for all. [Internet] [cited November 10, 2021] Toronto Star.
Google Scholar
18
-
Japan Oks administration of Pfizer COVID-19 vaccine booster shots. [Internet] [cited November 10, 2021] The Japan Times.
Google Scholar
19
-
Pfizer vaccine’s protection wanes over time, and not because of Delta, study says, [Internet] [cited October 4, 2021] Los Angeles Times.
Google Scholar
20
-
Shervani Z, Bhardwaj D, Nikhat R. Dharavi Slums (Mumbai, India): The Petri Dish of COVID-19 Herd Immunity. European Journal of Medical and Health Sciences. 2021; 3(3): 38-41.
DOI | Google Scholar
21
-
Shervani Z. COVID-19 in Kerala: Health Index Theory. European Journal of Medical and Health Sciences. 2021; 3(2): 21-24.
DOI | Google Scholar
22
-
Shervani Z. COVID-19 in Kerala: The Dynamics of Spread and Health Index Theory. RAS Medical Science. 2021; 1(2): 1-3.
DOI | Google Scholar
23
-
Shervani Z, Khan I, Siddiqui NY, Khan T, Qazi UY.Viability of SARS-CoV-2 and Sanitization Methods. European Journal of Medical and Health Sciences. 2021; 3(1): 22-27.
DOI | Google Scholar
24
-
Shervani Z, Khan I, Siddiqui NY, Khan T, Qazi UY. Risk of SARS-CoV-2 Transmission from Humans to Pets and Vice Versa. European Journal of Medical and Health Sciences. 2021; 3(1): 34-38.
DOI | Google Scholar
25
-
Shervani Z, Khan I, Qazi UY. Sars-cov-2 delayed Tokyo 2020 Olympics: Very recent advances in covid-19 detection, treatment, and vaccine development useful conducting the games in 2021. Advances in Infectious Diseases. 2020; 10(3): 56-66.
DOI | Google Scholar
26
-
Shervani Z, Khan I, Qazi UY. COVID-19 vaccine. Advances in Infectious Diseases. 2020; 10(3): 195-210.
DOI | Google Scholar
27
-
Shervani Z, Khan I, Khan T, Qazi UY. World’s fastest supercomputer picks COVID-19 drug. Advances in Infectious Diseases. 2020; 10(3): 211-225.
DOI | Google Scholar
28
-
Sharma N, Sharma P, Basu S, Bakshi R, Gupta E, Agarwal R, et al. Second wave of the Covid-19 pandemic in Delhi, India: high seroprevalence not a deterrent? Cureus. 2021; 13(10).
DOI | Google Scholar
29
-
https://www.indiaonlinepages.com/population/delhi-population.html.
Google Scholar
30
-
Over 50% exposer to Sars-Cov-2 in 10 of 11 city districts: serosurvey in Delhi. [Internet] [cited February 3, 2021] Hindustan Times.
Google Scholar
31
-
Delhi 6th Sero-survey: 97% of People Have COVID Antibodies, Says Health Minister. [Internet] [cited October 28, 2021] The Quint
Google Scholar
32
-
Delhi 6th sero-survey: More than 90% have antibodies. [Internet] [cited October 27, 2021] The Hindu.
Google Scholar
33
-
Herd Immunity for Delhi? As Sixth Sero Survey Finds Over 90% Have Antibodies, Here`s What it Means. [Internet] [cited October 28, 2021] News 18.
Google Scholar
34
-
Covid antibodies found in 97% of Delhi residents. [Internet] [cited October 29, 2021] Times of India.
Google Scholar
35
-
th Delhi sero survey shows 97% prevalence of antibodies. [Internet] [cited November 13, 2021] Hindustan Times.
Google Scholar
36
Most read articles by the same author(s)
-
Zameer Shervani,
Deepali Bhardwaj,
Roma Nikhat,
Dharavi Slums (Mumbai, India): The Petri Dish of COVID-19 Herd Immunity , European Journal of Medical and Health Sciences: Vol. 3 No. 3 (2021) -
Zameer Shervani,
Deepali Bhardwaj,
Roma Nikhat,
Aiman Ibbrahim,
Intazam Khan,
Umair Yaqub Qazi,
Ankira Agarwal,
Adil Ahmed Khan,
Sadia Hasan,
Abdullah Sherwani,
4th National Sero Survey of India: Vaccine Generated Antibodies Enhancement , European Journal of Medical and Health Sciences: Vol. 4 No. 1 (2022) -
Zameer Shervani,
Intazam Khan,
Noha Yamin Siddiqui,
Tooba Khan,
Umair Yaqub Qazi,
Risk of SARS-CoV-2 Transmission from Humans to Pets and Vice Versa , European Journal of Medical and Health Sciences: Vol. 3 No. 1 (2021) -
Zameer Shervani,
Intazam Khan,
Noha Yamin Siddiqui,
Tooba Khan,
Umair Yaqub Qazi,
Viability of SARS-CoV-2 and Sanitization Methods , European Journal of Medical and Health Sciences: Vol. 3 No. 1 (2021) -
Zameer Shervani,
Deepali Bhardwaj,
Manseej Purang,
Aiman Ibbrahim,
Venkata Phani Sai Reddy Vuyyuru,
Sadia Hasan,
Arif Siddiquie,
Umair Yaqub Qazi,
Adil Ahmed Khan,
Kehkeshan Fatma,
Samar Siddiqui,
Nudrat Jamal,
Shazma Khan,
Abdullah Sherwani,
The Omicron Variant: Prevalence, Transmissibility, and Pathogenicity , European Journal of Medical and Health Sciences: Vol. 4 No. 3 (2022) -
Zameer Shervani,
COVID-19 in Kerala: Health Index Theory , European Journal of Medical and Health Sciences: Vol. 3 No. 2 (2021) -
Zameer Shervani,
Deepali Bhardwaj,
Sadia Hasan,
Umair Yaqub Qazi,
Manseej Purang,
Aiman Ibbrahim,
Venkata Phani Sai Reddy Vuyyuru,
Arif Siddiquie,
Abdullah Sherwani,
Adil Ahmed Khan,
Kehkeshan Fatma,
Samar Siddiqui,
Nudrat Jamal,
Shazma Khan,
The Omicron Wave in India, Mumbai, and Delhi: Prevalence and Pathogenicity , European Journal of Medical and Health Sciences: Vol. 4 No. 3 (2022) -
Zameer Shervani,
Roma Nikhat,
Sadia Hasan,
Umair Yaqub Qazi,
Kehkeshan Fatma,
Arif Siddiquie,
Venkata Phani Sai Reddy Vuyyuru,
Nudrat Jamal,
Aiman Ibbrahim,
Samar Siddiqui,
Adil Ahmed Khan,
Parangimalai Diwakar Madan Kumar,
Manseej Purang,
Ankira Agarwal,
COVID-19 in India: Breakthrough Infections in Delta Wave , European Journal of Medical and Health Sciences: Vol. 4 No. 4 (2022) -
Zameer Shervani,
Deepali Bhardwaj,
Abdullah Sherwani,
Intazam Khan,
Umair Yaqub Qazi,
COVID-19 Infection in 8 Big Cities of India: The Dynamics of the Spread and Seropositivity , European Journal of Medical and Health Sciences: Vol. 3 No. 6 (2021) -
Zameer Shervani,
Deepali Bhardwaj,
Roma Nikhat,
COVID-19 Infection in India: Seropositivity versus the Dynamics of the Spread , European Journal of Medical and Health Sciences: Vol. 3 No. 4 (2021)